Aurinia Pharmaceuticals Inc (AUPH) Upgraded to “Hold” at Zacks Investment Research
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Monday.
According to Zacks, “Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company’s lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada. “
Several other research analysts also recently commented on the company. Leerink Swann restated an “outperform” rating and issued a $7.00 target price on shares of Aurinia Pharmaceuticals in a research note on Sunday, December 4th. FBR & Co restated an “outperform” rating and issued a $9.00 target price on shares of Aurinia Pharmaceuticals in a research note on Thursday, December 22nd. HC Wainwright cut their target price on Aurinia Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, December 30th. Finally, Canaccord Genuity restated a “buy” rating and issued a $10.00 target price on shares of Aurinia Pharmaceuticals in a research note on Friday, March 3rd. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $8.92.
Aurinia Pharmaceuticals (NASDAQ:AUPH) traded up 14.03% on Monday, hitting $8.78. The stock had a trading volume of 27,745,739 shares. The stock’s market capitalization is $469.10 million. Aurinia Pharmaceuticals has a 1-year low of $1.74 and a 1-year high of $10.54. The company has a 50-day moving average price of $4.73 and a 200-day moving average price of $3.34.
Your IP Address:
Several hedge funds have recently modified their holdings of the stock. Creative Planning acquired a new stake in shares of Aurinia Pharmaceuticals during the third quarter worth about $181,000. SG Americas Securities LLC acquired a new stake in shares of Aurinia Pharmaceuticals during the third quarter worth about $1,123,000. Redmile Group LLC increased its stake in shares of Aurinia Pharmaceuticals by 560.4% in the third quarter. Redmile Group LLC now owns 187,610 shares of the company’s stock worth $565,000 after buying an additional 159,200 shares during the period. Oxford Asset Management acquired a new stake in shares of Aurinia Pharmaceuticals during the fourth quarter worth about $211,000. Finally, Acuta Capital Partners LLC acquired a new stake in shares of Aurinia Pharmaceuticals during the fourth quarter worth about $2,100,000. Hedge funds and other institutional investors own 7.96% of the company’s stock.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Stock Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.